Modern strategy of anti-ischemic therapy for patients with chronic coronary syndromes


DOI: https://dx.doi.org/10.18565/therapy.2021.8.151-157

Lyamina N.P.

Moscow Center for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine of Moscow Healthcare Department
Abstract. The article is devoted to a review of foreign and domestic studies, which studied the therapy of chronic ischemic syndromes and cardiovascular complications in patients with coronary heart disease (CHD), taking into account the metabolism of cardiomyocytes. The modern view of myocardial ischemia pathogenesis from the standpoint of intracellular energy metabolism concept significantly expands the therapeutic approaches to solving this problem in clinical practice. In light of this, the use of trimetazidine (fatty acids beta-oxidation selective inhibitor) in the anti-ischemic therapy of chronic coronary syndromes is an important and justified component of complex treatment. This is confirmed by the results of numerous clinical studies in which the effectiveness of the use of trimetazidine was established in order to improve intracellular energy metabolism, reduce the severity and duration of ischemia periods.
Keywords: chronic ischemic syndromes, metabolism, trimetazidine, ischemic heart disease
Read entire article

Literature


  1. Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019; pii: ehz425. doi:10.1093/eurheartj/ehz425.

  2. Российское кардиологическое общество. Стабильная ишемическая болезнь сердца. Клинические рекомендации – 2020. Российский кардиологический журнал. 2020; 11: 4076. [Russian Society of Cardiology. 2020 Clinical practice guidelines for stable coronary artery disease. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 11: 4076 (In Russ.)]. https://doi.org/10.15829/29/1560-4071-2020-4076.

  3. Wu L., Luan Y., Li Y. et al. Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial. BMC Cardiovasc Disord. 2020; 20(1): 273. doi: 10.1186/s12872-020-01557-3.

  4. Marzilli M., Vinereanu D., Lopaschuk G. et al. Trimetazidine in cardiovascular medicine. Int J Cardiol. 2019; 293: 39–44. doi: 10.1016/j.ijcard.2019.05.06.

  5. Di Pasquale P., Verso Lo P., Bucca V. et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther. 1999; 13(5): 423–28. doi: 10.1023/a:1007804007115.

  6. Асташкин Е.И. Коррекция энергетического обмена в миокарде – новое направление в лечении сердечно-сосудистых заболеваний. Сердце и метаболизм. 2008; 21 :1–3. [Astashkin E.I. Correction of energy metabolism in the myocardium is a new direction in the treatment of cardiovascular diseases. Serdtse i metabolism = Heart and Metabolism. 2008; 21 :1–3 (In Russ.)].

  7. Михин В.П. Цитопротекция в кардиологии: достигнутые успехи и перспективы. Архивъ внутренней медицины. 2014; 1: 44–49. [Mikhin V.P. Cytoprotection in cardiology: achievements and prospects. Arkhiv vnutrenney meditsiny = Archives of Internal Medicine. 2014; 1: 44–49 (In Russ.)].

  8. Скотников А.С., Гороховская Г.Н., Шилов А.М. с соавт. Превентивная цитопротекция при социально значимых заболеваниях. Терапевтический архив. 2015; 8: 29–43. [Skotnikov A.S., Gorokhovskaya G.N., Shilov A.M. et al. Preventive cytoprotection in social diseases. Terapevticheskiy arkhiv = Therapeutic Archive. 2015; 8: 29–43 (In Russ.)]. https://doi.org/10.17116/terarkh201587829-43.

  9. Taqueti V.R., Di Carli M.F. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018; 72(21): 2625–41. doi: 10.1016/j.jacc.2018.09.042.

  10. Васюк Ю.А., Куликов К.Г., Кудряков О.Н., Крикунова О.В. Митохондриальная дисфункция в патогенезе острого инфаркта миокарда: принципы диагностики и терапии миокардиальными цитопротекторами. Российские медицинские вести. 2008; 2: 36–41. [Vasyuk Yu.A., Kulikov K.G., Kudryakov O.N., Krikunova O.V. Mitochondrial dysfunction in pathogenesis of myocardial infarction: principles of diagnostics and therapy by miocardial cytoprotectors. Rossiyskiye meditsinskiye vesti = Russian Medical News. 2008; 2: 36–41 (In Russ.)].

  11. Stone P.A., Kazil J. The relationships between serum C-reactive protein level and risk and progression of coronary and carotid atherosclerosis. Semin Vasc Surg. 2014; 27(3–4): 138–42. doi: 10.1053/j.semvascsurg.2015.04.002.

  12. Согласованное мнение экспертов о целесообразности использования миокардиального цитопротектора триметазидина (Предуктала МВ) в комплексной терапии больных с хроническими формами ишемической болезни сердца. CARDIOСОМАТИКА. 2012; 2: 58–64. [Expert consensus on the expediency of using the myocardial cytoprotector trimetazidine (Preductal MB) in the combination therapy of patients with chronic coronary heart. CARDIOSOMATIKA = CARDIOSOMATICS. 2012; 2: 58–64 (In Russ.)].

  13. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3- ketoacyl coenzyme A thiolase. Circ Res. 2000; 86(5): 580–88. doi: 10.1161/01.res.86.5.580.

  14. Montalescot G., Sechtem U., Achenbach S. et al. ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38): 2949–3003. doi: 10.1093/eurheartj/eht296.

  15. Kunadian V., Chieffo A., Camici P.G. et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020; 41(37): 3504–20. doi: 10.1093/eurheartj/ehaa503.

  16. Vitale C., Wajngaten M., Sposato B. et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004; 25(20): 1814–21. doi: 10.1016/j.ehj.2004.06.034.

  17. Аронов Д.М., Выгодин В.А., Новикова Н.К. с соавт. Сравнительная оценка влияния физических тренировок и триметазидина на динамику ишемии миокарда и показатели физической работоспособности больных ишемической болезнью сердца. Кардиоваскулярная терапия и профилактика. 2002; 4: 32–40. [Aronov D.M., Vygodin V.A., Novikova N.K. et al. Comparative assessment of the effect of physical training and trimetazidine on the dynamics of myocardial ischemia and indicators of physical performance in patients with ischemic heart disease. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2002; 4: 32–40 (In Russ.)].

  18. Grynberg A. [Role of membrane lipids in myocardial cytoprotection]. Arch Mal Coeur Vaiss. 2000; 93(2): 175–82.

  19. Shao S., Shi Z., Tse G. et al. Effects of trimetazidine pretreatment on endothelial dysfunction and myocardial injury in unstable angina patients undergoing percutaneous coronary intervention. Cardiol Res Pract. 2019; 2019: 4230948. doi: 10.1155/2019/4230948.

  20. Bertomeu-Gonzalez V., Bouzas-Mosquera A., Kaski J.C. Role of trimetazidine in management of ischemic cardiomyopathy. Am J Cardiol. 2006; 98(5A): 19J–24J. doi: 10.1016/j.amjcard.2006.07.005.

  21. Бубнова М.Г., Аронов Д.М., Оганов Р.Г., Рудоманов О.Г. Новые возможности триметазидина МВ в лечении ишемической болезни сердца в условиях реальной клинической практики. Результаты российского многоцентрового рандомизированного исследования «Перспектива» (часть II). Кардиоваскулярная терапия и профилактика. 2011; 6: 70–80. [Bubnova M.G., Aronov D.M., Oganov R.G., Rudomanov O.G. New potential of trimetazidine mb for coronary heart disease treatment in the real-world clinical practice: results of the Russian multi-centre randomised study «PERSPECTIVA» (part II). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2011; 6: 70–80 (In Russ.)]. https://doi.org/10.15829/1728-8800-2011-6-70-80.

  22. Махинова М.М. Клиническая эффективность персонализированной программы физических тренировок и селективного ингибитора бета-окисления жирных кислот в реабилитации больных с фибрилляцией предсердий после первичной радиочастотной аблации устьев легочных вен. Автореферат диссертации на соискание ученой степени кандидата медицинских наук. 2020. [Makhinova M.M. Clinical efficacy of a personalized exercise program and a selective inhibitor of beta-oxidation of fatty acids in the rehabilitation of patients with atrial fibrillation after primary radiofrequencyablation of the orifices of the pulmonary veins. Abstract of dissertation for the degree of candidate of medical sciences. 2020 (In Russ.)].

  23. Бубнова М.Г., Салманова А.С. Триметазидин МВ в повышении физической работоспособности и предупреждении ишемии миокарда у больных коронарной болезнью сердца после пищевой жировой нагрузки. Сердце: журнал для практикующих врачей. 2010; 5: 277–283. [Bubnova M.G., Salmanova A.S. Trimetazidine MV in improving physical performance and preventing myocardial ischemia in patients with coronary heart disease after a dietary fat load. Serdtse: zhurnal dlya praktikuyushchikh vrachey = Heart: the journal for medical practitioners. 2010; 5: 277–283 (In Russ.)].

  24. 24. Ciapponi A., Pizarro R., Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2005; 4: CD003614. doi: 10.1002/14651858.CD003614.pub2.

  25. 25. Peng S., Zhao M., Wan J. et al. The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trials. Int J Cardiol. 2014; 177(3): 780–85. doi: 10.1016/j.ijcard.2014.10.149.

  26. 26. Vitale C., Spoletini I., Malorni W. et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina – the VASCO-angina study. Int J Cardiol. 2013; 168(2): 1078–81. doi: 10.1016/j.ijcard.2012.11.001.

  27. Zhao P., Zhang J., Yin X.G. et al. The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci. 2013; 92(11): 633–38. doi: 10.1016/j.lfs.2012.03.015.

  28. Кечкер М.И., Лебедева Е.Л. Антиаритмический эффект триметазидина у больных ишемической болезнью сердца с экстрасистолией и парасистолией. Вестник аритмологии. 2003; 31: 26–31. [Kechker M.I., Lebedeva E.L. Antiarrhythmic effect of trimetazidine in patients with ischemic heart disease with extrasystole and parasystole. Vestnik aritmologii = Bulletin of Arrhythmology. 2003; 31: 26–31 (In Russ.)].

  29. Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л. с соавт. Исследование КАРДИОКАНОН: способ решения вопроса о клинической эквивалентности оригинальных и воспроизведенных препаратов. Рациональная фармакотерапия в кардиологии. 2012; 2: 179–84 [Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L., et al. The KARDIOKANON study: a way to settle the subject of clinical equivalence of generic and original drugs. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2012; 2: 179–84 (In Russ.)]. https://doi.org/10.20996/1819-6446-2012-8-2-54-55.

  30. Государственный реестр лекарственных средств Минздрава России. Инструкции к лекарственным препаратам с МНН триметазидин. Доступ: https://grls.rosminzdrav.ru (дата обращения – 01.10.2021). [State Register of Medicines of the Ministry of Healthcare of Russia. Instructions for medicinal products with INN trimetazidine. Available at: https://grls.rosminzdrav.ru (date of access – 01.10.2021) (In Russ.)].

  31. Kornicke T., Arora D., Samad A. et al. Single ascending dose study to assess pharmacokinetic linearity, safety, and tolerability of trimetazidine – modified release in healthy human subjects. Drug Res (Stuttg). 2020; 70(10): 472–77. doi: 10.1055/a-1180-4357.

  32. Bonello L., Sbragia P., Amabile N. et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart. 2007; 93(6): 703–07. doi: 10.1136/hrt.2006.107524.

  33. Галин П.Ю., Губанова Т.Г. Клиническая эффективность триметазидина МВ при микрососудистой стенокардии. Российский кардиологический журнал. 2016; 12: 84–89. [Galin P.Yu., Gubanova T.G. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2016; 12: 84–89 (In Russ.)]. http://dx.doi.org/10.15829/1560-4071-2016-12-84-89.

  34. Ромащенко О.В., Клочкова Г.Н., Муханова Е.И., Гайворонская И.В. Плейотропные эффекты триметазидина. Российский кардиологический журнал. 2013; 4: 83–7 [Romashchenko O.V., Klochkova G.N., Mukhanova E.I., Gaivoronskaia I.V. Pleiotropic effects of trimetazidine. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2013; 4: 83–87. (In Russ.)]. https://doi.org/10.15829/1560-4071-2013-4-83-87.

  35. Mahfoudh-Boussaid A., Hadj-Ayed K., Zaouali M.A. et al. Effects of trimetazidine on the Akt/eNOS signaling pathway and oxidative stress in an in vivo rat model of renal ischemia-reperfusion. Ren Fail. 2014; 36(9): 1436–42. doi: 10.3109/0886022X.2014.949765.

  36. Ibrahim T.A., El-Mawardy R.H., El-Serafy A.S., El-Fekky E.M. Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease. Cardiovasc Revasc Med. 2017; 18(5): 315–19. doi: 10.1016/j.carrev.2017.02.006.

  37. Hassanzadeh G., Hosseini A., Pasbakhsh P. et al. Trimetazidine prevents oxidative changes induced in a rat model of sporadic type of Alzheimer’s disease. Acta Med Iran. 2015; 53(1): 17–24.

  38. Shehata M. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention. Am J Cardiol. 2014; 114(3): 389–94. doi: 10.1016/j.amjcard.2014.04.052.

  39. Гиляров М.Ю., Константинова Е.В., Ковалец П.В. с соавт. Какие факторы ассоциированы с развитием контраст-индуцированной нефропатии у пациентов старческого возраста с острым коронарным синдромом в реальной клинической практике? Рациональная фармакотерапия в кардиологии. 2020; 6: 908–915 [Gilyarov M.Yu., Konstantinova E.V., Kovalets P.V. et al. What factors are associated with the development of contras-induced nephropathy in elderly patients with acute coronary syndrome in real clinical practice? Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2020; 6: 908–915 (In Russ.)]. https://dx.doi.org/10.20996/1819-6446-2020-12-02.

  40. Frishman W.H. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev. 2007; 15(5): 257–63. doi: 10.1097/CRD.0b013e3180cabbe7.


About the Autors

Nadezhda P. Lyamina, MD, professor, head of the Department of medical rehabilitation,
Moscow Center for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine of Moscow Healthcare Department. Address: Moscow, 53 Zemlyanoy val Str. E-mail: lyana_n@mail.ru. ORCID: 0000-0001-6939-3234


Similar Articles

Back to Content

Бионика Медиа